HK1204932A1 - Pharmaceutical composition for treatment of diabetic complications - Google Patents

Pharmaceutical composition for treatment of diabetic complications

Info

Publication number
HK1204932A1
HK1204932A1 HK15105526.5A HK15105526A HK1204932A1 HK 1204932 A1 HK1204932 A1 HK 1204932A1 HK 15105526 A HK15105526 A HK 15105526A HK 1204932 A1 HK1204932 A1 HK 1204932A1
Authority
HK
Hong Kong
Prior art keywords
treatment
pharmaceutical composition
diabetic complications
diabetic
complications
Prior art date
Application number
HK15105526.5A
Other languages
English (en)
Chinese (zh)
Inventor
蘇普里特‧
‧德什潘德
蘇迪爾‧
‧庫卡爾尼
雷納‧
‧格拉普迪
Original Assignee
Vlife Sciences Technologies Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlife Sciences Technologies Pvt Ltd filed Critical Vlife Sciences Technologies Pvt Ltd
Publication of HK1204932A1 publication Critical patent/HK1204932A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15105526.5A 2007-01-29 2015-06-10 Pharmaceutical composition for treatment of diabetic complications HK1204932A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1960MU2006 2007-01-29

Publications (1)

Publication Number Publication Date
HK1204932A1 true HK1204932A1 (en) 2015-12-11

Family

ID=47263792

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10104542.3A HK1137149A1 (en) 2007-01-29 2010-05-10 Pharmaceutical composition for treatment of diabetic complications
HK15105526.5A HK1204932A1 (en) 2007-01-29 2015-06-10 Pharmaceutical composition for treatment of diabetic complications

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK10104542.3A HK1137149A1 (en) 2007-01-29 2010-05-10 Pharmaceutical composition for treatment of diabetic complications

Country Status (11)

Country Link
US (1) US8686051B2 (xx)
EP (2) EP2114386B9 (xx)
JP (1) JP5240586B2 (xx)
CN (2) CN101616662B (xx)
CA (1) CA2680843C (xx)
CY (1) CY1113784T1 (xx)
DK (1) DK2114386T3 (xx)
ES (1) ES2400004T3 (xx)
HK (2) HK1137149A1 (xx)
WO (1) WO2008093356A1 (xx)
ZA (1) ZA200905970B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011039780A2 (en) 2009-09-22 2011-04-07 Vlife Sciences Technologies Pvt. Ltd. Topical formulation for diabetic foot ulcers
US20140356452A1 (en) * 2012-01-19 2014-12-04 Ibt Usa Inc. Therapeutic Uses of Tetrachlorodecaoxygen (TCDO)
CA2871070C (en) * 2012-04-20 2024-01-02 Howard University Method of treating an ocular disease and compositions effective for treating an ocular disease
EP2968374A4 (en) * 2013-03-15 2016-08-10 Alphabet 3 Llc M METHODS AND COMPOSITIONS FOR IMPROVING OXYGEN RATE IN FABRICS
US20160175485A1 (en) * 2013-08-27 2016-06-23 The Regents Of The University Of California Combination therapy to promote wound healing
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CN104971211A (zh) * 2014-04-02 2015-10-14 王嘉影 一种用于治疗糖尿病神经源性膀胱病的复方中药汤剂
WO2016108130A1 (en) * 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
CN105770860B (zh) * 2016-03-16 2021-01-05 哈尔滨医科大学 生长分化因子-11在促进糖尿病伤口愈合中的用途
EA201992515A1 (ru) * 2017-04-21 2020-04-09 Стивен Хоффман Композиции и способы для лечения ретинопатии
US20210059963A1 (en) * 2017-12-27 2021-03-04 Genepred Biotechnologies Beta-blockers for treating and/or preventing pathological scars
WO2019213358A1 (en) * 2018-05-03 2019-11-07 Alimera Sciences, Inc. Methods of treating retinal diseases
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
US11154518B2 (en) * 2018-12-28 2021-10-26 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound
TWI776584B (zh) * 2020-07-10 2022-09-01 長庚醫療財團法人林口長庚紀念醫院 β-1腎上腺素受體拮抗劑用於製備減少表皮生長因子受體抑制劑誘導的上皮細胞損傷以及抑制癌細胞的組合物之用途
CN114053419B (zh) * 2021-12-09 2023-02-24 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) 去甲肾上腺素或β-肾上腺素能受体抑制剂在制备治疗糖尿病神经修复的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL300886A (xx) * 1962-11-23
US3655663A (en) * 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US4593119A (en) * 1980-11-28 1986-06-03 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
JPS58206519A (ja) * 1982-05-27 1983-12-01 Kowa Co 外用β−遮断剤
US4897417A (en) 1988-12-15 1990-01-30 E. I. Du Pont De Nemours & Co. Prodrugs of 3,4-hydroxy benzoyloxypropanolamines
EP0677291A3 (en) * 1991-03-18 1996-08-07 Sepracor Inc Composition and method containing optically pure S-metoprolol.
AU770365B2 (en) 1998-12-11 2004-02-19 Bakulesh Mafatlal Khamar The process for manufacturing formulation of topical beta blockers with improved efficacy
WO2003059372A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and a modulator of diabetic late complications
US20100215710A1 (en) 2005-04-08 2010-08-26 The Regents Of The University Of California Beta-2 Adrenergic Receptor Agonists and Antagonists and Modulation of Wound Healing

Also Published As

Publication number Publication date
ES2400004T3 (es) 2013-04-04
EP2114386B1 (en) 2012-12-26
CA2680843A1 (en) 2008-08-07
CN101616662A (zh) 2009-12-30
EP2114386B9 (en) 2013-09-18
DK2114386T3 (da) 2013-03-18
US20110021526A1 (en) 2011-01-27
CA2680843C (en) 2016-05-31
JP2011509917A (ja) 2011-03-31
US8686051B2 (en) 2014-04-01
WO2008093356A1 (en) 2008-08-07
EP2114386A1 (en) 2009-11-11
EP2444077A1 (en) 2012-04-25
ZA200905970B (en) 2012-08-29
JP5240586B2 (ja) 2013-07-17
CN101616662B (zh) 2015-07-29
CY1113784T1 (el) 2016-07-27
CN104189906A (zh) 2014-12-10
HK1137149A1 (en) 2010-07-23

Similar Documents

Publication Publication Date Title
HK1204932A1 (en) Pharmaceutical composition for treatment of diabetic complications
ZA200902374B (en) Compositions useful for the treatment of diabetes
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
LT2303330T (lt) Farmacinės kompozicijos, skirtos parkinsono ligai gydyti
IL199907A0 (en) Composition for treatment of pancreatic cancer
IL200090A0 (en) Composition for treatment of undifferentiated-type of gastric cancer
EP3189859B8 (en) Composition for treatment of cartilage disease
PL2322221T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania raka
HK1141447A1 (en) Pharmaceutical composition for the treatment of proliferative diseases
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
EP2213303A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
GB0909297D0 (en) Composition for the treatment of skin conditions
EP2172207A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES AND METHOD FOR THE PRODUCTION THEREOF
GB2469220B (en) Pharmaceutical composition for treating diabetes and preparation method thereof
ZA201009072B (en) Pharmaceutical composition for the treatment of premature ejaculation
EP2210621A4 (en) COMPOSITION FOR THE TREATMENT OF JOINT DISEASES
EP2301543A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
HK1155659A1 (en) Pharmaceutical composition for treatment of fibromyalgia
PL385972A1 (pl) Kompozycja farmaceutyczna do leczenia chorób przyzębia
PL2305300T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi
ZA201204341B (en) Pharmaceutical composition for treating gutaneous burns
EP2402342A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
HK1145399A1 (en) Pharmaceutical composition for treating hemorrhoids
EP2382992A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADIPOSITAS OR DIABETES
EP2331099A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS